Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and ...

Discover comprehensive details about Nusinersen, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- Upper ...

Across the studies of a new analysis, there was a significant risk difference in motor milestone response and improvement in Hammersmith Infant Neurological Examination score. Although more ...

According to the researchers, the findings are paving the way toward precision medicine and may have broader use in tracking treatment response in adult-onset motor neuropathy in the future. A recent ...

New treatment option for spinal muscular atrophy moves closer to EU approval Biogen has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has ...

Children with later-onset spinal muscular atrophy benefited from three years of treatment with the anti-sense oligonucleotide nusinersen, according to a paper in today’s Neurology. Motor function ...

The appraisal committee (section 5) considered evidence submitted by Biogen Idec and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the ...

Nusinersen injection is injected intrathecally (into the backbone) over 1-3 minutes so that it reaches the cerebrospinal fluid (CSF), the fluid that bathes the brain and the spinal cord. Dosage & When ...

Nusinersen is an antisense oligonucleotide drug that modulates pre–messenger RNA splicing of the survival motor neuron 2 (SMN2) gene. It has been developed for the treatment of spinal muscular atrophy ...